Capital International Investors
SWTX

Capital International Investors’s SpringWorks Therapeutics SWTX Stock Holding History

Capital International Investors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,143
Closed -$1.99M – 470
2025
Q1 		$1.99M Sell
45,143
-2,316,603
-98% -$107M ﹤0.01% 417
2024
Q4 		$85.3M Buy
2,361,746
+1,136,079
+93% +$39.7M 0.02% 302
2024
Q3 		$39.3M Buy
+1,225,667
New +$45.8M 0.01% 344

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

Capital International Investors's SWTX Position: Q2 2025 in Review

Capital International Investors sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 45,143 shares — an estimated $1.99M sold.

Capital International Investors first reported a position in SWTX in Q3 2024 and held it in 3 quarters. The position peaked at $85.3M in Q4 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Capital International Investors reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Capital International Investors sold 45,143 SpringWorks Therapeutics shares in Q2 2025, an estimated $1.99M.
  • Capital International Investors first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 3 quarters.
  • Capital International Investors's SpringWorks Therapeutics position peaked at $85.3M in Q4 2024.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Capital International Investors's 13F filing for Q2 2025, filed 13 Aug 2025.